nad has been researched along with Kahler Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elnenaei, MO; Gujar, SA; Kennedy, BE; Reiman, A; Sadek, M | 1 |
| Ali, SA; Borrello, IM; de Souza Fernandes Pereira, M; Elmas, E; Ghiaur, G; Imus, PH; Lee, DA; Naeimi Kararoudi, M; Nagai, Y; Wethington, D | 1 |
| Aguennouz, M; Alibrandi, A; Allegra, A; Allegra, AG; Di Giorgio, RM; Innao, V; Musolino, C; Oteri, G; Oteri, R; Polito, F | 1 |
| Bam, R; Barlogie, B; Epstein, J; Khan, S; Li, X; Ling, W; Usmani, S; van Rhee, F; Venkateshaiah, SU; Yaccoby, S | 1 |
| Acharya, C; Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Fulciniti, M; Gobbi, M; Hideshima, T; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Tai, YT; Zhong, MY | 1 |
| Beauparlant, P; Bédard, D; Bernier, C; Chan, H; Gilbert, K; Goulet, D; Gratton, MO; Lavoie, M; Roulston, A; Turcotte, E; Watson, M | 1 |
| Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Cottini, F; Fulciniti, M; Gobbi, M; Hideshima, T; Jakubikova, J; Kong, SY; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Roccaro, A; Sacco, A; Tai, YT | 1 |
| Anderson, KC; Cagnetta, A; Cea, M; Gobbi, M; Nencioni, A; Patrone, F | 1 |
| AURICCHIO, S; QUAGLIARIELLO, E; RINALDI, E; VIOLANTE, A | 1 |
| Ehrhart, H; Hörmann, W; Kienle, H | 1 |
10 other study(ies) available for nad and Kahler Disease
| Article | Year |
|---|---|
Targeting NAD
Topics: Acrylamides; Adenosine; Adenosine Diphosphate Ribose; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytokines; Drug Synergism; Humans; Membrane Glycoproteins; Multiple Myeloma; NAD; Niacinamide; Nicotinamide Phosphoribosyltransferase; Piperidines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Escape; Warburg Effect, Oncologic | 2020 |
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.
Topics: Adoptive Transfer; ADP-ribosyl Cyclase 1; Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; CRISPR-Cas Systems; Cytotoxicity, Immunologic; Humans; Immunotherapy; Killer Cells, Natural; Male; Membrane Glycoproteins; Mice; Mice, Inbred NOD; Multiple Myeloma; NAD; Oxidative Phosphorylation; Specific Pathogen-Free Organisms; Tretinoin; Whole Genome Sequencing | 2020 |
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma.
Topics: Aged; Biomarkers; Bone Diseases; Case-Control Studies; Female; Gene Expression Regulation, Neoplastic; Glutathione Peroxidase; Healthy Volunteers; Humans; Hydrogen Peroxide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; NAD; Oxidation-Reduction; Oxidative Stress; Sirtuin 2; Sirtuin 3 | 2021 |
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Topics: Acrylamides; Animals; Bone and Bones; Cell Differentiation; Coculture Techniques; Cytokines; Enzyme Induction; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Proteins; NF-kappa B; Niacinamide; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Osteoclasts; Osteolysis; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Rabbits; Sirtuin 1; Tumor Cells, Cultured; Up-Regulation | 2013 |
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
Topics: Acrylamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Case-Control Studies; Caspases; Cell Proliferation; Drug Synergism; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Recurrence, Local; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Oligonucleotide Array Sequence Analysis; Piperidines; Poly(ADP-ribose) Polymerases; Prognosis; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Colonic Neoplasms; Cyanides; Cytokines; Drug Screening Assays, Antitumor; Female; Guanidines; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Proteins; Niacin; Niacinamide; Nicotinamide Phosphoribosyltransferase; Prodrugs; Xenograft Model Antitumor Assays | 2009 |
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Topics: Acrylamides; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Multiple Myeloma; Multiprotein Complexes; NAD; Nicotinamide Phosphoribosyltransferase; Organ Specificity; Piperidines; Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.
Topics: Acrylamides; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Lentivirus; Multiple Myeloma; NAD; Piperidines; Transcription, Genetic | 2013 |
On the effect of DPN on the conversion of 3-hydroxyanthranilic acid to quinolinic acid in presence of hepatic tissue of rats affected by Oberling's myeloma in the leukemic phase.
Topics: 3-Hydroxyanthranilic Acid; Animals; Coenzymes; Leukemia; Leukemia, Myeloid; Liver; Multiple Myeloma; NAD; Pyridines; Quinolinic Acid; Rats | 1958 |
[Quantitative changes of coenzymes and substrates of Glycolysis in rat-Myeloma following cytostatic therapy with C 73 in various dosage].
Topics: Adenine Nucleotides; Adenosine Triphosphate; Alkylating Agents; Animals; Coenzymes; Glycolysis; Multiple Myeloma; NAD; Neoplasms, Experimental; Rats | 1970 |